Finding 1221220 (2025-001)

Material Weakness Repeat Finding
Requirement
P
Questioned Costs
-
Year
2025
Accepted
2026-06-29
Audit: 405578
Organization: Bmc Health System, Inc. (MA)
Auditor: KPMG LLP

AI Summary

  • Core Issue: The Health System lacks proper documentation and controls for Workday changes and user access reviews.
  • Impacted Requirements: Testing and approval evidence missing for changes; separation of duties not enforced; privileged access not consistently managed.
  • Recommended Follow-Up: Establish a centralized process for documentation, enhance UAR procedures to prevent self-review, and expand the scope to include all privileged access reviews.

Finding Text

Condition 1. The Health System performed and documented a Workday change review during the fiscal year; however, we noted appropriate evidence of testing and/or approval was not maintained for 4 of 25 sampled changes during the period. 2. The Health System performed a Workday User Access Review (UAR) during the fiscal year and maintained certain evidence demonstrating the UAR occurred; however, management did not retain the screenshot of the Workday report utilized for the User Access Review (UAR). Additionally, the individual performing the review also had access to the system, resulting in the individual reviewing and validating their own access. 3. Management did not consistently implement controls to ensure that privileged user access was limited to active individuals in support of their roles and responsibilities. Specifically, there were five vendors with Implementer access, which enables the implementation and migration of changes, who did not require that level of access during the period. Cause The conditions above relate to the following, respectively: 1. The condition occurred because the Health System did not have a centralized process for maintaining evidence of testing and approval for changes. 2. The condition occurred because the Health System did not include processes to implement separation of duties controls when the reviewer was included in the population or processes to include screenshots of the listing used to support the completeness and accuracy of the list. 3. This condition occurred because Implementer access was not included as part of the Workday UAR. Recommendation We recommend that management review and emphasize the change management policies and procedures with key personnel and establish a centralized process to ensure that evidence related to the review, testing, and approval of all Workday changes is maintained. Additionally, we recommend that management enhance the Workday UAR process to incorporate segregation of duties, preventing individuals from reviewing their own access, and to ensure that documentation, such as system-generated reports or screenshots, is retained to support the completeness and accuracy of the review. The scope of the UAR should be expanded to formally include a review of all privileged-level access, such as the Implementer role, to ensure this access is appropriate and promptly removed when no longer required.

Corrective Action Plan

The Health System will take the following actions to resolve the noted conditions: 1. To address the noted conditions for user access reviews the Health System will update SOPs and documentation in two separate areas: a. Vendors/Consultants that do work for the Health System will be instructed to only move changes to production with explicit written approval from the business leader of the Human Resources (HR) function or Human Resources Information Systems (HRIS) leadership. Verbal approval in meetings will be insufficient. The updated requirement will be communicated to all business leads in HR. b. Workday Releases are currently reviewed and tested by HRIS prior to implementation. During testing, the auditors noted two releases that did not have documentation of testing. The two releases relate to modules or functionality not used by the Health System. HRIS will update its practice of reviewing Workday releases to include documentation on release items that do not apply to the Health System and, therefore, do not require testing. This change will be incorporated in HRIS’s SOP and communicated to the team conducting the Workday release reviews. 2. HRIS leadership will update its SOP for UAR to require screenshot of the system generated report used for the UAR and require an HR VP to review the Sr. Manager’s (primary individual doing review) access. The HRIS team will be trained on the updates to the new SOP. 3. We have done a comprehensive review of our implementers/vendors and began disabling them from our systems when they no longer require access to our systems upon completion of services. HR business leads will be required to request implementor/vendor access disablement on the completion of their work. The HR business leads will be trained on this process. As a new additional control, implementers/vendors will be reviewed by HRIS on an annual basis mirroring the current security review process for other users. Person Responsible: Karen Alvarado – Senior Manager HRIS E-mail address: Karen.Alvarado@bmc.org

Categories

HUD Housing Programs Internal Control / Segregation of Duties

Other Findings in this Audit

  • 1220932 2025-001
    Material Weakness Repeat
  • 1220933 2025-001
    Material Weakness Repeat
  • 1220934 2025-001
    Material Weakness Repeat
  • 1220935 2025-001
    Material Weakness Repeat
  • 1220936 2025-001
    Material Weakness Repeat
  • 1220937 2025-001
    Material Weakness Repeat
  • 1220938 2025-001
    Material Weakness Repeat
  • 1220939 2025-001
    Material Weakness Repeat
  • 1220940 2025-001
    Material Weakness Repeat
  • 1220941 2025-001
    Material Weakness Repeat
  • 1220942 2025-001
    Material Weakness Repeat
  • 1220943 2025-001
    Material Weakness Repeat
  • 1220944 2025-001
    Material Weakness Repeat
  • 1220945 2025-001
    Material Weakness Repeat
  • 1220946 2025-001
    Material Weakness Repeat
  • 1220947 2025-001
    Material Weakness Repeat
  • 1220948 2025-001
    Material Weakness Repeat
  • 1220949 2025-001
    Material Weakness Repeat
  • 1220950 2025-001
    Material Weakness Repeat
  • 1220951 2025-001
    Material Weakness Repeat
  • 1220952 2025-001
    Material Weakness Repeat
  • 1220953 2025-001
    Material Weakness Repeat
  • 1220954 2025-001
    Material Weakness Repeat
  • 1220955 2025-001
    Material Weakness Repeat
  • 1220956 2025-001
    Material Weakness Repeat
  • 1220957 2025-001
    Material Weakness Repeat
  • 1220958 2025-001
    Material Weakness Repeat
  • 1220959 2025-001
    Material Weakness Repeat
  • 1220960 2025-001
    Material Weakness Repeat
  • 1220961 2025-001
    Material Weakness Repeat
  • 1220962 2025-001
    Material Weakness Repeat
  • 1220963 2025-001
    Material Weakness Repeat
  • 1220964 2025-001
    Material Weakness Repeat
  • 1220965 2025-001
    Material Weakness Repeat
  • 1220966 2025-001
    Material Weakness Repeat
  • 1220967 2025-001
    Material Weakness Repeat
  • 1220968 2025-001
    Material Weakness Repeat
  • 1220969 2025-001
    Material Weakness Repeat
  • 1220970 2025-001
    Material Weakness Repeat
  • 1220971 2025-001
    Material Weakness Repeat
  • 1220972 2025-001
    Material Weakness Repeat
  • 1220973 2025-001
    Material Weakness Repeat
  • 1220974 2025-001
    Material Weakness Repeat
  • 1220975 2025-001
    Material Weakness Repeat
  • 1220976 2025-001
    Material Weakness Repeat
  • 1220977 2025-001
    Material Weakness Repeat
  • 1220978 2025-001
    Material Weakness Repeat
  • 1220979 2025-001
    Material Weakness Repeat
  • 1220980 2025-001
    Material Weakness Repeat
  • 1220981 2025-001
    Material Weakness Repeat
  • 1220982 2025-001
    Material Weakness Repeat
  • 1220983 2025-001
    Material Weakness Repeat
  • 1220984 2025-001
    Material Weakness Repeat
  • 1220985 2025-001
    Material Weakness Repeat
  • 1220986 2025-001
    Material Weakness Repeat
  • 1220987 2025-001
    Material Weakness Repeat
  • 1220988 2025-001
    Material Weakness Repeat
  • 1220989 2025-001
    Material Weakness Repeat
  • 1220990 2025-001
    Material Weakness Repeat
  • 1220991 2025-001
    Material Weakness Repeat
  • 1220992 2025-001
    Material Weakness Repeat
  • 1220993 2025-001
    Material Weakness Repeat
  • 1220994 2025-001
    Material Weakness Repeat
  • 1220995 2025-001
    Material Weakness Repeat
  • 1220996 2025-001
    Material Weakness Repeat
  • 1220997 2025-001
    Material Weakness Repeat
  • 1220998 2025-001
    Material Weakness Repeat
  • 1220999 2025-001
    Material Weakness Repeat
  • 1221000 2025-001
    Material Weakness Repeat
  • 1221001 2025-001
    Material Weakness Repeat
  • 1221002 2025-001
    Material Weakness Repeat
  • 1221003 2025-001
    Material Weakness Repeat
  • 1221004 2025-001
    Material Weakness Repeat
  • 1221005 2025-001
    Material Weakness Repeat
  • 1221006 2025-001
    Material Weakness Repeat
  • 1221007 2025-001
    Material Weakness Repeat
  • 1221008 2025-001
    Material Weakness Repeat
  • 1221009 2025-001
    Material Weakness Repeat
  • 1221010 2025-001
    Material Weakness Repeat
  • 1221011 2025-001
    Material Weakness Repeat
  • 1221012 2025-001
    Material Weakness Repeat
  • 1221013 2025-001
    Material Weakness Repeat
  • 1221014 2025-001
    Material Weakness Repeat
  • 1221015 2025-001
    Material Weakness Repeat
  • 1221016 2025-001
    Material Weakness Repeat
  • 1221017 2025-001
    Material Weakness Repeat
  • 1221018 2025-001
    Material Weakness Repeat
  • 1221019 2025-001
    Material Weakness Repeat
  • 1221020 2025-001
    Material Weakness Repeat
  • 1221021 2025-001
    Material Weakness Repeat
  • 1221022 2025-001
    Material Weakness Repeat
  • 1221023 2025-001
    Material Weakness Repeat
  • 1221024 2025-001
    Material Weakness Repeat
  • 1221025 2025-001
    Material Weakness Repeat
  • 1221026 2025-001
    Material Weakness Repeat
  • 1221027 2025-001
    Material Weakness Repeat
  • 1221028 2025-001
    Material Weakness Repeat
  • 1221029 2025-001
    Material Weakness Repeat
  • 1221030 2025-001
    Material Weakness Repeat
  • 1221031 2025-001
    Material Weakness Repeat
  • 1221032 2025-001
    Material Weakness Repeat
  • 1221033 2025-001
    Material Weakness Repeat
  • 1221034 2025-001
    Material Weakness Repeat
  • 1221035 2025-001
    Material Weakness Repeat
  • 1221036 2025-001
    Material Weakness Repeat
  • 1221037 2025-001
    Material Weakness Repeat
  • 1221038 2025-001
    Material Weakness Repeat
  • 1221039 2025-001
    Material Weakness Repeat
  • 1221040 2025-001
    Material Weakness Repeat
  • 1221041 2025-001
    Material Weakness Repeat
  • 1221042 2025-001
    Material Weakness Repeat
  • 1221043 2025-001
    Material Weakness Repeat
  • 1221044 2025-001
    Material Weakness Repeat
  • 1221045 2025-001
    Material Weakness Repeat
  • 1221046 2025-001
    Material Weakness Repeat
  • 1221047 2025-001
    Material Weakness Repeat
  • 1221048 2025-001
    Material Weakness Repeat
  • 1221049 2025-001
    Material Weakness Repeat
  • 1221050 2025-001
    Material Weakness Repeat
  • 1221051 2025-001
    Material Weakness Repeat
  • 1221052 2025-001
    Material Weakness Repeat
  • 1221053 2025-001
    Material Weakness Repeat
  • 1221054 2025-001
    Material Weakness Repeat
  • 1221055 2025-001
    Material Weakness Repeat
  • 1221056 2025-001
    Material Weakness Repeat
  • 1221057 2025-001
    Material Weakness Repeat
  • 1221058 2025-001
    Material Weakness Repeat
  • 1221059 2025-001
    Material Weakness Repeat
  • 1221060 2025-001
    Material Weakness Repeat
  • 1221061 2025-001
    Material Weakness Repeat
  • 1221062 2025-001
    Material Weakness Repeat
  • 1221063 2025-001
    Material Weakness Repeat
  • 1221064 2025-001
    Material Weakness Repeat
  • 1221065 2025-001
    Material Weakness Repeat
  • 1221066 2025-001
    Material Weakness Repeat
  • 1221067 2025-001
    Material Weakness Repeat
  • 1221068 2025-001
    Material Weakness Repeat
  • 1221069 2025-001
    Material Weakness Repeat
  • 1221070 2025-001
    Material Weakness Repeat
  • 1221071 2025-001
    Material Weakness Repeat
  • 1221072 2025-001
    Material Weakness Repeat
  • 1221073 2025-001
    Material Weakness Repeat
  • 1221074 2025-001
    Material Weakness Repeat
  • 1221075 2025-001
    Material Weakness Repeat
  • 1221076 2025-001
    Material Weakness Repeat
  • 1221077 2025-001
    Material Weakness Repeat
  • 1221078 2025-001
    Material Weakness Repeat
  • 1221079 2025-001
    Material Weakness Repeat
  • 1221080 2025-001
    Material Weakness Repeat
  • 1221081 2025-001
    Material Weakness Repeat
  • 1221082 2025-001
    Material Weakness Repeat
  • 1221083 2025-001
    Material Weakness Repeat
  • 1221084 2025-001
    Material Weakness Repeat
  • 1221085 2025-001
    Material Weakness Repeat
  • 1221086 2025-001
    Material Weakness Repeat
  • 1221087 2025-001
    Material Weakness Repeat
  • 1221088 2025-001
    Material Weakness Repeat
  • 1221089 2025-001
    Material Weakness Repeat
  • 1221090 2025-001
    Material Weakness Repeat
  • 1221091 2025-001
    Material Weakness Repeat
  • 1221092 2025-001
    Material Weakness Repeat
  • 1221093 2025-001
    Material Weakness Repeat
  • 1221094 2025-001
    Material Weakness Repeat
  • 1221095 2025-001
    Material Weakness Repeat
  • 1221096 2025-001
    Material Weakness Repeat
  • 1221097 2025-001
    Material Weakness Repeat
  • 1221098 2025-001
    Material Weakness Repeat
  • 1221099 2025-001
    Material Weakness Repeat
  • 1221100 2025-001
    Material Weakness Repeat
  • 1221101 2025-001
    Material Weakness Repeat
  • 1221102 2025-001
    Material Weakness Repeat
  • 1221103 2025-001
    Material Weakness Repeat
  • 1221104 2025-001
    Material Weakness Repeat
  • 1221105 2025-001
    Material Weakness Repeat
  • 1221106 2025-001
    Material Weakness Repeat
  • 1221107 2025-001
    Material Weakness Repeat
  • 1221108 2025-001
    Material Weakness Repeat
  • 1221109 2025-001
    Material Weakness Repeat
  • 1221110 2025-001
    Material Weakness Repeat
  • 1221111 2025-001
    Material Weakness Repeat
  • 1221112 2025-001
    Material Weakness Repeat
  • 1221113 2025-001
    Material Weakness Repeat
  • 1221114 2025-001
    Material Weakness Repeat
  • 1221115 2025-001
    Material Weakness Repeat
  • 1221116 2025-001
    Material Weakness Repeat
  • 1221117 2025-001
    Material Weakness Repeat
  • 1221118 2025-001
    Material Weakness Repeat
  • 1221119 2025-001
    Material Weakness Repeat
  • 1221120 2025-001
    Material Weakness Repeat
  • 1221121 2025-001
    Material Weakness Repeat
  • 1221122 2025-001
    Material Weakness Repeat
  • 1221123 2025-001
    Material Weakness Repeat
  • 1221124 2025-001
    Material Weakness Repeat
  • 1221125 2025-001
    Material Weakness Repeat
  • 1221126 2025-001
    Material Weakness Repeat
  • 1221127 2025-001
    Material Weakness Repeat
  • 1221128 2025-001
    Material Weakness Repeat
  • 1221129 2025-001
    Material Weakness Repeat
  • 1221130 2025-001
    Material Weakness Repeat
  • 1221131 2025-001
    Material Weakness Repeat
  • 1221132 2025-001
    Material Weakness Repeat
  • 1221133 2025-001
    Material Weakness Repeat
  • 1221134 2025-001
    Material Weakness Repeat
  • 1221135 2025-001
    Material Weakness Repeat
  • 1221136 2025-001
    Material Weakness Repeat
  • 1221137 2025-001
    Material Weakness Repeat
  • 1221138 2025-001
    Material Weakness Repeat
  • 1221139 2025-001
    Material Weakness Repeat
  • 1221140 2025-001
    Material Weakness Repeat
  • 1221141 2025-001
    Material Weakness Repeat
  • 1221142 2025-001
    Material Weakness Repeat
  • 1221143 2025-001
    Material Weakness Repeat
  • 1221144 2025-001
    Material Weakness Repeat
  • 1221145 2025-001
    Material Weakness Repeat
  • 1221146 2025-001
    Material Weakness Repeat
  • 1221147 2025-001
    Material Weakness Repeat
  • 1221148 2025-001
    Material Weakness Repeat
  • 1221149 2025-001
    Material Weakness Repeat
  • 1221150 2025-001
    Material Weakness Repeat
  • 1221151 2025-001
    Material Weakness Repeat
  • 1221152 2025-001
    Material Weakness Repeat
  • 1221153 2025-001
    Material Weakness Repeat
  • 1221154 2025-001
    Material Weakness Repeat
  • 1221155 2025-001
    Material Weakness Repeat
  • 1221156 2025-001
    Material Weakness Repeat
  • 1221157 2025-001
    Material Weakness Repeat
  • 1221158 2025-001
    Material Weakness Repeat
  • 1221159 2025-001
    Material Weakness Repeat
  • 1221160 2025-001
    Material Weakness Repeat
  • 1221161 2025-001
    Material Weakness Repeat
  • 1221162 2025-001
    Material Weakness Repeat
  • 1221163 2025-001
    Material Weakness Repeat
  • 1221164 2025-001
    Material Weakness Repeat
  • 1221165 2025-001
    Material Weakness Repeat
  • 1221166 2025-001
    Material Weakness Repeat
  • 1221167 2025-001
    Material Weakness Repeat
  • 1221168 2025-001
    Material Weakness Repeat
  • 1221169 2025-001
    Material Weakness Repeat
  • 1221170 2025-001
    Material Weakness Repeat
  • 1221171 2025-001
    Material Weakness Repeat
  • 1221172 2025-001
    Material Weakness Repeat
  • 1221173 2025-001
    Material Weakness Repeat
  • 1221174 2025-001
    Material Weakness Repeat
  • 1221175 2025-001
    Material Weakness Repeat
  • 1221176 2025-001
    Material Weakness Repeat
  • 1221177 2025-001
    Material Weakness Repeat
  • 1221178 2025-001
    Material Weakness Repeat
  • 1221179 2025-001
    Material Weakness Repeat
  • 1221180 2025-001
    Material Weakness Repeat
  • 1221181 2025-001
    Material Weakness Repeat
  • 1221182 2025-001
    Material Weakness Repeat
  • 1221183 2025-001
    Material Weakness Repeat
  • 1221184 2025-001
    Material Weakness Repeat
  • 1221185 2025-001
    Material Weakness Repeat
  • 1221186 2025-001
    Material Weakness Repeat
  • 1221187 2025-001
    Material Weakness Repeat
  • 1221188 2025-001
    Material Weakness Repeat
  • 1221189 2025-001
    Material Weakness Repeat
  • 1221190 2025-001
    Material Weakness Repeat
  • 1221191 2025-001
    Material Weakness Repeat
  • 1221192 2025-001
    Material Weakness Repeat
  • 1221193 2025-001
    Material Weakness Repeat
  • 1221194 2025-001
    Material Weakness Repeat
  • 1221195 2025-001
    Material Weakness Repeat
  • 1221196 2025-001
    Material Weakness Repeat
  • 1221197 2025-001
    Material Weakness Repeat
  • 1221198 2025-001
    Material Weakness Repeat
  • 1221199 2025-001
    Material Weakness Repeat
  • 1221200 2025-001
    Material Weakness Repeat
  • 1221201 2025-001
    Material Weakness Repeat
  • 1221202 2025-001
    Material Weakness Repeat
  • 1221203 2025-001
    Material Weakness Repeat
  • 1221204 2025-001
    Material Weakness Repeat
  • 1221205 2025-001
    Material Weakness Repeat
  • 1221206 2025-001
    Material Weakness Repeat
  • 1221207 2025-001
    Material Weakness Repeat
  • 1221208 2025-001
    Material Weakness Repeat
  • 1221209 2025-001
    Material Weakness Repeat
  • 1221210 2025-001
    Material Weakness Repeat
  • 1221211 2025-001
    Material Weakness Repeat
  • 1221212 2025-001
    Material Weakness Repeat
  • 1221213 2025-001
    Material Weakness Repeat
  • 1221214 2025-001
    Material Weakness Repeat
  • 1221215 2025-001
    Material Weakness Repeat
  • 1221216 2025-001
    Material Weakness Repeat
  • 1221217 2025-001
    Material Weakness Repeat
  • 1221218 2025-001
    Material Weakness Repeat
  • 1221219 2025-001
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.940 HIV Prevention Activities Health Department Based $2.83M
93.945 Assistance Programs for Chronic Disease Prevention and Control $2.07M
93.838 Lung Diseases Research $1.68M
93.839 BLOOD DISEASES AND RESOURCES RESEARCH $1.13M
12.420 Military Medical Research and Development $869,095
93.136 Injury Prevention and Control Research and State and Community Based Programs $809,120
93.884 Primary Care Training and Enhancement $752,247
93.732 Mental and Behavioral Health Education and Training Grants $748,667
16.575 Crime Victim Assistance $616,531
93.186 National Research Service Award in Primary Care Medicine $559,178
93.959 Block Grants for Prevention and Treatment of Substance Abuse $555,140
93.117 Preventive Medicine Residency $497,085
93.073 Birth Defects and Developmental Disabilities - Prevention and Surveillance $486,113
93.225 National Research Service Awards Health Services Research Training $420,670
93.928 Special Projects of National Significance $381,527
93.088 Advancing System Improvements for Key Issues in Women's Health $373,327
93.153 Coordinated Services and Access to Research for Women, Infants, Children, and Youth $350,135
93.877 Autism Collaboration, Accountability, Research, Education, and Support $336,747
93.604 Assistance for Torture Victims $323,043
93.788 Opioid STR $263,501
93.351 Research Infrastructure Programs $238,257
12.RD National Defense, Emergency Preparedness, and Energy Program $218,171
93.307 Minority Health and Health Disparities Research $173,645
93.213 Research and Training in Complementary and Integrative Health $165,424
10.331 Gus Schumacher Nutrition Incentive Program $160,009
93.110 Special Projects of Regional and National Significance $157,854
93.173 Research Related to Deafness and Communication Disorders $155,701
93.273 Alcohol Research Programs $142,380
93.997 Assisted Outpatient Treatment $140,871
93.RD Centers for Disease Control and Prevention $125,162
93.113 Environmental Health $116,197
93.353 21st Century Cures Act - Beau Biden Cancer Moonshot $101,401
93.396 Cancer Biology Research $100,694
10.569 Emergency Food Assistance Program (Food Commodities) $98,261
93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders $98,088
93.361 Nursing Research $89,777
16.588 Violence Against Women Formula Grants $88,563
93.368 21st Century Cures Act - Precision Medicine Initiative $82,250
93.121 Oral Diseases and Disorders Research $80,814
93.839 Blood Diseases and Resources Research $79,452
93.686 Ending the HIV Epidemic: A Plan for America - Ryan White HIV/AIDS Program Parts A and B $79,395
93.817 Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities $78,383
93.846 Arthritis, Musculoskeletal and Skin Diseases Research $75,956
93.U01 Veterans Health Administration $74,815
93.217 Family Planning Services $63,710
93.394 Cancer Detection and Diagnosis Research $62,459
93.989 International Research and Research Training $60,361
93.U02 Centers for Disease Control and Prevention $56,330
16.745 Criminal and Juvenile Justice and Mental Health Collaboration Program $51,084
93.365 Sickle Cell Treatment Demonstration Program $49,776
94.006 AmeriCorps State and National 94.006 $45,471
94.013 AmeriCorps Volunteers In Service to America 49.013 $45,347
93.334 The Healthy Brain Initiative: Technical Assistance to Implement Public Health Actions related to Cognitive Health, Cognitive Impairment, and Caregiving at the State and Local Levels $43,458
93.840 Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders $38,041
93.243 Substance Abuse and Mental Health Services Projects of Regional and National Significance $33,377
93.350 National Center for Advancing Translational Sciences $30,303
93.226 Research on Healthcare Costs, Quality and Outcomes $24,359
93.310 Trans-NIH Research Support $22,344
93.279 Drug Use and Addiction Research Programs $22,237
93.242 Mental Health Research Grants $21,323
93.866 Aging Research $17,721
93.191 Graduate Psychology Education $16,815
93.172 Human Genome Research $14,098
93.421 Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation’s Health $12,184
94.021 AmeriCorps Volunteer Generation Fund 94.021 $11,114
10.001 Agricultural Research Basic and Applied Research $10,914
93.837 Cardiovascular Diseases Research $7,780
93.867 Vision Research $7,617
93.044 Special Programs for the Aging, Title III, Part B, Grants for Supportive Services and Senior Centers $7,003
93.127 Family to Family Health Information Centers $2,004
93.395 Cancer Treatment Research $791
47.074 Biological Sciences $407
93.397 Cancer Centers Support Grants $210
93.143 NIEHS Superfund Hazardous Substances_Basic Research and Educ $8
16.560 National Institute of Justice Research, Evaluation, and Deve $1
93.393 Cancer Cause and Prevention Research $-175
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $-216
93.592 Family Violence Prevention and Services/Discretionary $-952
93.914 HIV Emergency Relief Project Grants $-1,620
93.084 Prevention of Disease, Disability, and Death by Infectious Diseases $-2,613
14.231 Emergency Solutions Grant Program $-3,208
93.829 Section 223 Demonstration Programs to Improve Community Ment $-6,049
93.958 Block Grants for Community Mental Health Services $-9,522
93.855 Allergy and Infectious Diseases Research $-10,374
93.865 Child Health and Human Development Extramural Research $-10,586
93.994 Maternal and Child Health Services Block Grant to the States $-36,013
93.RD National Institutes of Health $-139,976